Literature DB >> 453704

Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies.

G W Comstock, C Baum, D E Snider.   

Abstract

As a result of numerous trials, isoniazid prophylaxis was shown to be effective in preventing tuberculosis in many different populations and under a variety of conditions. However, the duration of the protective effect has been of some concern. In a previous report, the protective effect of isoniazid prophylaxis among Alaskan Eskimos was shown to persist through the fifteenth year after its administration. In this final report, the protective effect is shown to persist for more than 19 years. The magnitude of the effect is related to the amount of isoniazid taken. The results of the study are consistent with the hypothesis that the decrease in risk of tuberculosis produced by isoniazid preventive therapy is lifelong.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 453704     DOI: 10.1164/arrd.1979.119.5.827

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  58 in total

1.  Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.

Authors:  Jonathan E Golub; Silvia Cohn; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Betina Durovni; Richard E Chaisson
Journal:  Clin Infect Dis       Date:  2014-11-02       Impact factor: 9.079

2.  New developments in BCG vaccine: implications for tuberculosis control.

Authors:  C R MacIntyre
Journal:  Epidemiol Infect       Date:  2007-02       Impact factor: 2.451

3.  Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis.

Authors:  S Raychaudhuri; R Shmerling; J Ermann; S Helfgott
Journal:  Rheumatology (Oxford)       Date:  2007-03-15       Impact factor: 7.580

4.  Re-examining treatment of latent tuberculosis infection.

Authors:  B Lynn Johnston; J M Conly
Journal:  Can J Infect Dis       Date:  2001-07

5.  Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.

Authors:  David W Dowdy; Jonathan E Golub; Valeria Saraceni; Lawrence H Moulton; Solange C Cavalcante; Silvia Cohn; Antonio G Pacheco; Richard E Chaisson; Betina Durovni
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-15       Impact factor: 3.731

6.  Epidemiology of tuberculosis in remote native communities.

Authors:  T K Young
Journal:  Can Fam Physician       Date:  1982-01       Impact factor: 3.275

7.  Estimating the mutation rate of Mycobacterium tuberculosis during infection.

Authors:  David R Sherman; Sebastien Gagneux
Journal:  Nat Genet       Date:  2011-05       Impact factor: 38.330

8.  Prevalent tuberculosis at HIV diagnosis in Rio de Janeiro, Brazil: the TB/HIV in Rio (THRio) Cohort.

Authors:  Valeria Saraceni; Silvia Cohn; Solange C Cavalcante; Antonio G F Pacheco; Lawrence H Moulton; Richard E Chaisson; Betina Durovni; Jonathan E Golub
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

9.  Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users.

Authors:  Jonathan E Golub; Jacquie Astemborski; Mohammed Ahmed; Wendy Cronin; Shruti H Mehta; Gregory D Kirk; David Vlahov; Richard E Chaisson
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

10.  A replication clock for Mycobacterium tuberculosis.

Authors:  Wendy P Gill; Nada S Harik; Molly R Whiddon; Reiling P Liao; John E Mittler; David R Sherman
Journal:  Nat Med       Date:  2009-02-01       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.